Información del artículo
El Texto completo está disponible en PDF
Bibliogrífia
[1.]
J.I. Esteban, R. Esteban, L. Viladomiu, J.C. López-Talavera, A. González, J.M. Hernández, et al.
Hepatitis C virus antibodies among risk groups in Spain.
Lancet, 2 (1989), pp. 294-297
[2.]
S.A. Villano, D. Vlahov, K.E. Nelson, C.M. Lyles, S. Cohn, D.L. Thomas.
Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland.
J Clin Microbiol, 35 (1997), pp. 3274-3277
[3.]
S. Sauleda, J.I. Esteban, C. Altisent, L. Puig, R. Esteban, J. Guardia.
Treatment with Interferon plus Ribavirin in anti-HIV negative patients with congenital coagulation disorders and chronic hepatitis C.
Thromb Haem, 83 (2000), pp. 807-810
[4.]
J.M. Hernández, S. Sauleda, Ll. Massuet, J.I. Esteban, R. Esteban, J. Guardia.
HCV genotype distribution among HCV positive blood donors and outpatients according to epidemiological features [abstract 304].
AABB Annual Meeting, San Francisco, (1999),
[5.]
H. Ohto, S. Terazawa, N. Sasaki, N. Sasaki, K. Hino, C. Ishiwata, et al.
Transmission of hepatitis C virus from mothers to infants.
New Engl J Med, 330 (1994), pp. 744-750
[6.]
P. Manzini, G. Saracco, A. Cerchier, C. Riva, A. Musso, E. Ricotti, et al.
Human immunodeficiency virus infection as risk factor for mother-to-child hepatitis C virus transmission; persistence of anti-hepatitis C virus in children is associated with the mother’s anti-hepatitis C virus immunoblotting pattern.
Hepatology, 21 (1995), pp. 328-332
[7.]
D.L. Thomas, S.A. Villano, K.A. Riester, R. Hershow, L.M. Mofenson, S.H. Landesman, et al.
Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers.
J Infect Dis, 177 (1998), pp. 1480-1488
[8.]
A.R. Zanetti, E. Tanzi, S. Paccagnini, N. Principi, G. Pizzocolo, M.L. Caccamo, et al.
Mother-to-infant transmission of hepatitis C virus. Lombardy Study Group on vertical HCV transmission.
Lancet, 345 (1995), pp. 289-291
[9.]
M.E. Eyster, H.J. Alter, L.M. Aledort, S. Quan, A. Hatzakis, J.J. Goedert.
Heterosexual cotransmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV).
Ann Inter Med, 15 (1991), pp. 764-768
[10.]
K. Bj(ro, S.S. Froland, Z. Yun, H.H. Samdal, T. Haaland.
Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin.
N Engl J Med, 331 (1994), pp. 1607-1611
[11.]
P. Martin, A.M. Di Bisceglie, C. Kassianides, M. Lisker-Melman, J.H. Hoofnagle.
Rapidly progressive non A non B hepatitis in patients with HIV infection.
Gastroenterology, 97 (1989), pp. 1559-1561
[12.]
K.E. Sherman, J. O’Brien, A.G. Gutierrez, S. Harrison, M. Urdea, P. Neuwald, et al.
Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infection.
J Clin Microbiol, 31 (1993), pp. 2679-2682
[13.]
M.E. Eyster, M.W. Fried, A.M. Di Bisceglie, J.J. Goedert.
Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus and liver disease. Multicenter Hemophilia Cohort Study.
Blood, 84 (1994), pp. 1020-1023
[14.]
D.L. Thomas, J.W. Shih, H.J. Alter, D. Vlahov, S. Cohn, D.R. Hoover, et al.
Effect of human immunodeficiency syndrome virus on hepatitis C virus infection among injecting drug users.
J Infect Dis, 174 (1996), pp. 690-695
[15.]
M.E. Eyster, L.S. Diamondstone, J.M. Lien, W.C. Ehmann, S. Quan, J.J. Goedert.
Natural history of hepatitis C virus infection in multitransfused hemophiliacs. Effect of coinfection with human immunodeficiency virus. Multicenter Hemophilia Cohort Study.
J Acquir Immune Defic Syndr, 6 (1993), pp. 602-610
[16.]
S.C. Darby, D.W. Ewart, P.L. Giangrande, R.J. Spooner, C.R. Rizza, G.M. Dusheiko, et al.
Mortality from liver cancer and liver disease in hemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors’ Organisation.
Lancet, 15 (1997), pp. 1425-1431
[17.]
O. Lesens, M. Deschenes, M. Steben, G. Belanger, C.M. Tsoukas.
Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection.
J Infect Dis, 79 (1999), pp. 1254-1258
[18.]
M. Makris, F.E. Preston, F.R. Rosendaal, J.C. Underwood, K.M. Rice, D.R. Triger.
The natural history of chronic hepatitis C in hemophiliacs.
Br J Hematol, 94 (1996), pp. 746-752
[19.]
S. Pol, B. Lamorthe, N.T. Thi, V. Thiers, F. Carnot, H. Zylberberg, et al.
Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users.
J Hepatol, 28 (1998), pp. 945-950
[20.]
V. Soriano, J. García-Samaniego, E. Valencia, R. Rodríguez-Rosado, F. Munoz, J. Gonzalez-Lahoz.
Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users.
Eur J Epidemiol, 15 (1999), pp. 1-4
[21.]
E. Bierhoff, H.P. Fischer, E. Willsch, J. Rockstroh, U. Spengler, H.H. Brackmann, et al.
Liver histopathology in patients with concurrent chronic hepatitis C and HIV infection.
Virchows Arch, 43 (1997), pp. 271-277
[22.]
J. García-Samaniego, V. Soriano, J. Castilla, R. Bravo, A. Moreno, J. Carbo, et al.
Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C. Hepatitis/ HIV Spanish Study Group.
Am J Gastroenterol, 92 (1997), pp. 1130-1134
[23.]
Y. Benhamou, M. Bochet, V. Di Martino, F. Charlotte, F. Azria, A. Coutellier, et al.
Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients.
Hepatology, 30 (1999), pp. 1054-1058
[24.]
P. Telfer, C. Sabin, H. Devereux, F. Scott, G. Dusheiko, C. Lee.
The progression of HCV-associated liver disease in a cohort of hemophilic patients.
Br J Hematol, 97 (1994), pp. 555-561
[25.]
B. Soto, A. Sánchez-Quijano, L. Rodrigo, J.A. del Olmo, M. García-Bengoechea, J. Hernández-Quero, et al.
Human immunodeficiency virus infection modifies the natural history of chronic parenterally acquired hepatitis C with an unusually rapid progression to cirrhosis.
J Hepatol, 26 (1997), pp. 1-5
[26.]
A. Sánchez-Quijano, J. Andreu, F. Gavilán, F. Luque, M.A. Abad, B. Soto, et al.
Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquiered hepatitis C.
Eur J Clin Microbiol Infect Dis, 14 (1995), pp. 949-953
[27.]
G. Dubin, M.N. Braffman.
Zidovudine-induced hepatotoxicity.
Ann Intern Med, 110 (1989), pp. 381-388
[28.]
J.R. Arribas, C. Ibáñez, B. Ruiz-Antoran, J.M. Pena, C. Esteban-Calvo, J. Frías, et al.
Acute hepatitis in HIV-infected patients during ritonavir treatment.
AIDS, 12 (1998), pp. 1722-1724
[29.]
R. Rodríguez-Rosado, J. García-Samaniego, V. Soriano.
Hepatotoxicity after introduction of highly active antiretroviral therapy.
AIDS, 12 (1998), pp. 1256
[30.]
M. John, J. Flexman, M.A. French.
Hepatitis C virus-associated hepatitis following treatment of HCV infected patients with HIV protease inhibitors: An immune restoration disease?.
AIDS, 12 (1998), pp. 2289-2293
[31.]
M. Puoti, F. Gargiulo, E.Q. Roldan, A. Chiodera, L. Palvarini, A. Spinetti, et al.
Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during early phases of combination antiretroviral treatment.
J Infect Dis, 181 (2000), pp. 2033-2036
[32.]
M.S. Sulkowski, D.L. Thomas, R.E. Chaisson, R.D. Moore.
Hepatotoxicity associated with antiretroviral therapy in adults with HIV and role of hepatitis B or C infection.
JAMA, 283 (2000), pp. 74-80
[33.]
R. Palmon, et al.
Hepatotoxicity associated with non nucleoside reverse transcriptase inhibitors for the treatment of human immunodeficiency virus and the effect of hepatitis B or C virus infection [abstract 610].
AASLD Annual Meeting; Dallas, (2000),
[34.]
N. Boyer, P. Marcellin, C. Degott, F. Degos, A.G. Saimot, S. Erlinger, et al.
Recombinant interferon-alpha for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus.
J Infect Dis, 165 (1992), pp. 723-726
[35.]
E. Marriott, S. Navas, J. del Romero, S. García, I. Castillo, J.A. Quiroga, et al.
Treatment with recombinant alpha-interferon of chronic hepatitis C in anti-HIV positive patients.
J Med Virol, 40 (1993), pp. 107-111
[36.]
V. Soriano, J. García-Samaniego, R. Bravo, J. González, A. Castro, J. Castilla, et al.
Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group.
Clin Infect Dis, 23 (1996), pp. 585-591
[37.]
S. Mauss, H. Klinker, A. Ulmer, R. Willers, B. Weissbrich, H. Albrecht, et al.
Response to treatment of chronic hepatitis C with interferon alpha in patients infected with HIV-1 is associated with higher CD4+ cell count.
Infection, 26 (1998), pp. 16-19
[38.]
X. Causse, J.L. Payen, J. Izopet, G. Babany, M.F. Girardin.
Does HIV infection influence the response of chronic hepatitis C to interferon treatment?.
A French multicenter prospective study. J Hepatol, 32 (2000), pp. 1003-1010
[39.]
S. Coll, et al.
Treatment of hepatitis C HIV-coinfected patients with interferon: Controlled study [abstract 153].
AASLD; Dallas, (1999),
[40.]
R. Bruno, et al.
Daily interferon therapy in HIV-HCV coinfected patients: Preliminary report [abstract 760].
AASLD Annual Meeting; Dallas, (2000),
[41.]
J.G. McHutchison, S.C. Gordon, E.R. Schiff, M.L. Shiffman, W.M. Lee, V.K. Rustgi, et al.
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C.
N Engl J Med, 339 (1998), pp. 1485-1492
[42.]
G.L. Davis, R. Esteban-Mur, V. Rustgi, J. Hoefs, S.C. Gordon, C. Trepo, et al.
Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C.
N Engl J Med, 339 (1998), pp. 1493-1499
[43.]
A. Landau, D. Batisse, C. Piketty, J.P. Duong Van Huyen, F. Bloch, L. Belec, et al.
Long-term efficacy of combination therapy with interferon-alfa 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients.
AIDS, 15 (2001), pp. 2149-2155
[44.]
G. Morsica, A. De Bona, C.U. Foppa, G. Sitia, R. Finazzi, A. Lazzarin.
Ribavirin therapy for chronic hepatitis C does not modify HIV viral load in HIV-1 positive patients under antiretroviral treatment.
AIDS, 14 (2000), pp. 1656-1658
[45.]
D.T. Dieterich, et al.
Combination treatment with interferon (IFN) and ribavirin (RBV) for hepatitis C (HCV) in HIV coinfected patients [abstract 422].
AASLD Annual Meeting, Dallas, (1999),
[46.]
H. Zylberberg, Y. Benhamou, J.L. Lagneaux, A. Landau, M.L. Chaix, H. Fontaine, et al.
Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report.
Gut, 47 (2000), pp. 696-697
[47.]
S. Sauleda, A. Juarez, J.I. Esteban, C. Altisent, I. Ruiz, L. Puig, et al.
Interferon and Ribavirin combination therapy for chronic hepatitis C in HIV-infected patients with congenital coagulation disorders.
Hepatology, 34 (2001), pp. 1035-1040
[48.]
M.W. Vogt, K.L. Hartshorn, P.A. Furman, T.C. Chou, J.A. Fyfe, L.A. Coleman, et al.
Ribavirin antagonizes the effect of azidothymidine on HIV replication.
Science, 235 (1987), pp. 1376-1379
[49.]
A. Landau, D. Batisse, C. Piketty, R. Jian, M.D. Kazatchkine.
Lack of interference between ribavirin and nucleoside analogues in HIV/HCV coinfected individuals undergoing concomitant antiretroviral and anti-HCV combination therapy.
AIDS, 14 (2000), pp. 1857-1858
[50.]
Y. Gerard, L. Maulin, Y. Yazdanpanah, X. De La Tribonniere, C. Amiel, C.A. Maurage, et al.
Symptomatic hyperlactatemia: an emerging complication of antiretroviral therapy.
AIDS, 14 (2000), pp. 2723-2730
[51.]
K. Brinkman.
Management of hyperlactatemia: no need for routine lactate measurements.
AIDS, 15 (2001), pp. 795-797
[52.]
A. Lafeuillade, G. Hittinger, S. Chadapaud.
Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection.
Lancet, 357 (2001), pp. 280-281
[53.]
D. Salmon-Ceron, L. Chauvelot-Moachon, S. Abad, B. Silbermann, P. Sogni.
Mitochondrial toxicity effects and ribavirin.
Lancet, 357 (2001), pp. 1803-1804
Copyright © 2002. Elsevier España, S.L.. Todos los derechos reservados
